Avita Medical Ltd. (AVMXY: OTCQX International) | Avita

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Avita Medical Ltd. (AVMXY: OTCQX International) | Avita Medical Enrolls First Patients in ReCell Trial for Chronic Leg Ulcers

?    65-PATIENT, RANDOMIZED, CONTROLLED STUDY OF VENOUS LEG ULCERS AT UP TO FIVE EUROPEAN CENTRES

?    LEG ULCERS CHARACTERISED BY HIGH TREATMENT COSTS; MAJOR BURDEN ON PATIENTS AND HEALTH CARE SYSTEMS

?    LARGE AND GROWING MARKET IN NEED OF NEW TREATMENT OPTIONS; US$25 BILLION LOWER LIMB MANAGEMENT MARKET IN US

?    SIGNIFICANT NEW MARKET OPPORTUNITY FOR RECELL

 

Regenerative medicine Company Avita Medical Ltd. (ASX: AVH ), ( OTC: AVMXF ), ( OTCQX:AVMXY ) announced the initial enrollment of three patients in the RESTORE trial, a multi-centre, randomized European clinical trial evaluating the use of ReCell? Spray-on Skin? in the management of patients with venous leg ulcers. The company believes the management and treatment of lower limb ulcers (LLUs) represents a large and growing market opportunity for ReCell.

LLUs:  A Significant and Costly Healthcare Problem

Lower limb ulcers (LLUs), which include venous leg ulcers (VLU) and diabetic foot ulcers (DFU), are a major healthcare problem in developed countries due to their prevalence, high cost of treatment and significant impact on patient quality of life.  LLUs afflict nearly 1.5% of the general population in OECD countries and up to 3% over the age of 70 years. Venous ulcers account for 75-85% of all leg ulcers and are anticipated to increase in prevalence with the growing elderly population.

The expense of treating LLUs imposes a major financial burden on healthcare systems globally.  In the US alone over 6.5 million people suffer from LLUs with associated treatment cost estimated in excess of US$25 billion; the UK National Health Service (NHS) estimate cost of treatment of LLUs at ?2-3 billion per year with similar prevalence and expense documented throughout other European countries. The costs to patients include associated morbidity, pain, lack of mobility and lost work days and wages.

Current treatment options include compression therapy, skin grafts and regular dressing changes; however, such options are costly and there is currently no effective or definitive treatment for LLUs. ReCell offers a promising potential to address this major unmet clinical need.

ReCell: The RESTORE Study

The RESTORE study is a randomized, controlled trial designed to evaluate the effectiveness of ReCell for the treatment of chronic venous leg ulcers and is targeting enrollment of 65 patients. The study is based on positive preliminary results achieved with the use of ReCell in the treatment of over 50 VLU patients as previously published (e.g., Giraldi et al, 2012; De Angelis et al, 2013).

The initial three patients in the RESTORE study, each of which have had unhealed ulcers for a minimum of 12 months, were enrolled under Investigator Mr Paul Hayes, consultant vascular and endovascular surgeon at the Addenbrooke?s Hospital in Cambridge, UK.  Following a two-week observation period, patients will be randomly assigned for treatment with ReCell or the current standard of care and will be followed for a minimum of 12 weeks post-treatment.  It is anticipated that additional study centres in Denmark, France and Germany will participate in the trial.

?Chronic wounds, of which venous leg ulcers are the most common, are a major burden to patients, health care professionals, and health care systems globally ,? said William Dolphin, CEO of Avita Medical. ?Preliminary results with the use of ReCell have been extremely encouraging and we are confident that this study will demonstrate the clinical efficacy of ReCell in treating lower limb ulcers.  Chronic wounds represent a large and growing market throughout the world and we believe that ReCell will provide an important treatment option for a large segment of this population. The chronic wound market represents a major market opportunity for the company and one for which there is currently no effective solution.?  

ABOUT AVITA MEDICAL LTD.

Avita Medical ( http://www.avitamedical.com/) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects.  Avita?s patented and proprietary tissue?culture, collection and application technology provides innovative treatment solutions derived from a patient?s own skin. The Company?s lead product, ReCell? Spray?On Skin?, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE?marked for Europe, TGA?registered in Australia, and SFDA?cleared in China. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process .

# # #

FOR FURTHER INFORMATION:

Contact:

Avita Medical Ltd.

Sharoni Billik

Investor Relations

Northridge CA, 91324 USA

Phone:+1 818 827-1675

Email: sbillik@avitamedical.com

 

Investor Relations:

Philip Capital

Sean Kennedy

Melbourne VIC 3000 Australia

Phone: +61 3 8633 9836

Email: skennedy@phillipcapital.com.au

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Lear’s PACE Award Matters Beyond Seat Warmers Today

Updated Category News Views 0

Seat foam and wiring seldom make investors sit upright, yet Lear has managed to turn that unglamorous corner of the vehicle into something worth watching. The company’s Modular Thermal Comfort Systems just won a 2026 Automotive News PACE Award, a respected supplier-industry nod for innovation and business performance. Awards alone do not pay anybody’s bills, and I...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 247

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 240

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 211

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 157

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 46

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 140

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 40

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
HashKey and Base Aim to Bridge Asia With Liquidity

Updated Category News Views 109

A blockchain partnership can sound like confetti until the plumbing matters. This one at least points at a real commercial choke point: Asian-originated tokenized assets need deeper pools of global onchain capital, while global networks need credible asset supply and institutional access. HashKey Group's HSK Chain and Coinbase-built Base say they intend to tackle both...

Continue Reading

Top 5 Most Recently Viewed Articles

Qubic's Game-Changing Milestone in Proof of Work Innovation

Updated Category News Views 335

Revolutionizing Mining: Qubic's Major Milestone Qubic, a decentralized compute and AI Layer 1 protocol, has reached a significant milestone with the successful implementation of its Useful Proof of Work (uPoW) concept. By harnessing the potential of merge mining with Monero and Tari, Qubic is setting a new standard in the mining industry and redefining the dynamics of...

Continue Reading
Global Ship Lease's Strong Q3 2024 Performance and Future Outlook

Updated Category News Views 187

Global Ship Lease Reports Impressive Third Quarter of 2024 Global Ship Lease, Inc. (NYSE: GSL), a key player in the containership ownership market, has recently revealed its unaudited financial results for the third quarter of 2024, reflecting strong operational performance and strategic positioning in an evolving maritime landscape. Quarterly Highlights: A Solid...

Continue Reading
Silverfort's New Security Features Enhance Identity Protection

Updated Category News Views 210

Enhancing Identity Security with Silverfort's New Capabilities Silverfort has recently announced exciting advancements in its identity security solutions, solidifying its leadership within the emerging identity verification and identity protection (IVIP) market. The introduction of Access Intelligence and Identity Graph & Inventory empowers organizations to proactively...

Continue Reading
Gabelli Multimedia Trust Maintains Steady Monthly Dividends

Updated Category News Views 306

Gabelli Multimedia Trust's Commitment to Shareholders The Gabelli Multimedia Trust Inc. (NYSE: GGT), located in RYE, N.Y., has reaffirmed its commitment to provide regular monthly cash distributions for its shareholders. This initiative emphasizes the Fund's dedication to maintaining a stable income stream, reflecting its solid financial strategies aimed at long-term...

Continue Reading
Shabodi Launches NetAware 2.1 to Transform Network Applications

Updated Category News Views 170

Shabodi Unveils NetAware 2.1: A Game-Changer for Programmable Networks Shabodi has proudly announced the launch of its innovative platform, NetAware 2.1, marking another significant stride in the realm of programmable networks. This advanced version embodies Shabodi's commitment to enhancing network-aware applications, offering a suite of capabilities that empower...

Continue Reading